Health Economics and Outcomes Research

Intensified regimens improve event-free survival and overall survival in patients newly diagnosed with diffuse large B-cell lymphoma compared with standard therapy.
A recent analysis reports a cost-effective alternative modality that demonstrates similar efficacy to traditional breast MRI.
Patients with diffuse large B-cell lymphoma benefit from improved survival outcomes when treated with a combination therapy rather than monotherapy.
Mitigation strategies may save up to 17% annually in parenteral anticancer drug costs.
Women who have been treated for early-stage breast cancer and receive surveillance testing are at risk of adverse events and increased financial burden.
Certain therapy options for early-stage breast cancer have fewer associated complications and are much less expensive than others.